{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:33:09Z","timestamp":1793118789944,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijcard.2025.133554","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T10:51:39Z","timestamp":1750762299000},"page":"133554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Diabetic cardiomyopathy revisited: The interplay between diabetes and heart failure"],"prefix":"10.1016","volume":"438","author":[{"given":"Christopher","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Zelniker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijcard.2025.133554_bb0005","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133554_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am. J. Cardiol."},{"issue":"24","key":"10.1016\/j.ijcard.2025.133554_bb0015","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1161\/CIRCULATIONAHA.118.034986","article-title":"Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus","volume":"138","author":"McAllister","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ijcard.2025.133554_bb0020","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ehf2.13930","article-title":"Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation","volume":"9","author":"Hofer","year":"2022","journal-title":"ESC Heart Fail."},{"issue":"16","key":"10.1016\/j.ijcard.2025.133554_bb0025","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2021.08.020","article-title":"Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults","volume":"78","author":"Segar","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2025.133554_bb0030","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cardfail.2014.02.007","article-title":"The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota","volume":"20","author":"Dandamudi","year":"2014","journal-title":"J. Card. Fail."},{"issue":"7","key":"10.1016\/j.ijcard.2025.133554_bb0035","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ijcard.2025.133554_bb0040","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.numecd.2023.12.013","article-title":"Prevalence and clinical characteristics of diabetic cardiomyopathy in patients with acute heart failure","volume":"34","author":"Matsushita","year":"2024","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"7","key":"10.1016\/j.ijcard.2025.133554_bb0045","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/diacare.22.7.1186","article-title":"Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes","volume":"22","author":"Berg","year":"1999","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ijcard.2025.133554_bb0050","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00125-022-05821-3","article-title":"Advanced glycation end-products, cardiac function and heart failure in the general population: the Rotterdam Study","volume":"66","author":"Arshi","year":"2023","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.ijcard.2025.133554_bb0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/eurjhf\/hfp070","article-title":"Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db\/db type 2 diabetic mice","volume":"11","author":"Nielsen","year":"2009","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.ijcard.2025.133554_bb0060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF00805570","article-title":"Glycosylation enhances oxygen radical-induced modifications and decreases acetylhydrolase activity of human low density lipoprotein","volume":"92","author":"Napoli","year":"1997","journal-title":"Basic Res. Cardiol."},{"issue":"22","key":"10.1016\/j.ijcard.2025.133554_bb0065","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1053\/euhj.2001.2655","article-title":"Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1","volume":"22","author":"Liguori","year":"2001","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133554_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12933-021-01357-9","article-title":"Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial","volume":"20","author":"Verdonschot","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"12","key":"10.1016\/j.ijcard.2025.133554_bb0075","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jcmg.2010.09.014","article-title":"Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes","volume":"3","author":"Sacre","year":"2010","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"3","key":"10.1016\/j.ijcard.2025.133554_bb0080","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jacc.2005.09.030","article-title":"Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus","volume":"47","author":"Herrero","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133554_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-023-01811-w","article-title":"Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation","volume":"22","author":"Gopal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"17","key":"10.1016\/j.ijcard.2025.133554_bb0090","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1161\/CIRCULATIONAHA.105.554360","article-title":"Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity","volume":"112","author":"Boudina","year":"2005","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ijcard.2025.133554_bb0095","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.jacc.2009.07.031","article-title":"Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart","volume":"54","author":"Anderson","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2025.133554_bb0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/FJC.0000000000001228","article-title":"What role do mitochondria have in diastolic dysfunction? Implications for diabetic cardiomyopathy and heart failure with preserved ejection function","volume":"79","author":"McCandless","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133554_bb0105","doi-asserted-by":"crossref","first-page":"H118","DOI":"10.1152\/ajpheart.00932.2010","article-title":"Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways","volume":"300","author":"Anderson","year":"2011","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"10.1016\/j.ijcard.2025.133554_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.17733","article-title":"Differential changes in cyclic adenosine 3\u2032-5\u2032 monophosphate (cAMP) effectors and major ca 2+ handling proteins during diabetic cardiomyopathy","author":"Chaoul","year":"2023","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2025.133554_bb0115","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ehf2.14224","article-title":"Diabetic cardiomyopathy: a brief summary on lipid toxicity","volume":"10","author":"Ke","year":"2023","journal-title":"ESC Heart Fail."},{"issue":"4","key":"10.1016\/j.ijcard.2025.133554_bb0120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pcad.2019.03.003","article-title":"Diabetic cardiomyopathy - a comprehensive updated review","volume":"62","author":"Murtaza","year":"2019","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2025.133554_bb0125","doi-asserted-by":"crossref","first-page":"110805","DOI":"10.1016\/j.diabres.2023.110805","article-title":"Type 1 diabetes and risk of heart failure: a systematic review and meta-analysis","author":"Haji","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"8","key":"10.1016\/j.ijcard.2025.133554_bb0130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jchf.2021.05.019","article-title":"Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes","volume":"9","author":"Packer","year":"2021","journal-title":"JACC Heart Fail."},{"issue":"19","key":"10.1016\/j.ijcard.2025.133554_bb0135","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.3390\/ijms21197412","article-title":"p38 MAPK pathway in the heart: new insights in health and disease","volume":"21","author":"Romero-Becerra","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ijcard.2025.133554_bb0140","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacbts.2018.04.003","article-title":"Potentiation of insulin signaling contributes to heart failure in type 2 diabetes","volume":"3","author":"Packer","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133554_bb0145","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12916-020-01688-6","article-title":"Insulin: too much of a good thing is bad","volume":"18","author":"Kolb","year":"2020","journal-title":"BMC Med."},{"issue":"24","key":"10.1016\/j.ijcard.2025.133554_bb0150","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ijcard.2025.133554_bb0155","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ijcard.2025.133554_bb0160","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis","volume":"10","author":"Kanie","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"17","key":"10.1016\/j.ijcard.2025.133554_bb0165","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ijcard.2025.133554_bb0170","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ijcard.2025.133554_bb0175","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2025.133554_bb0180","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2025.133554_bb0185","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2025.133554_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.15420\/cfr.2018.44.1","article-title":"Treatment of heart failure with sodium-glucose cotransporter 2 inhibitors and other anti-diabetic drugs","volume":"5","author":"Zelniker","year":"2019","journal-title":"Card. Fail. Rev."},{"issue":"21","key":"10.1016\/j.ijcard.2025.133554_bb0195","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2025.133554_bb0200","first-page":"ehad192","article-title":"ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ijcard.2025.133554_bb0205","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1373\/clinchem.2018.298489","article-title":"Cardiac and inflammatory biomarkers are associated with worsening renal outcomes in patients with type 2 diabetes mellitus: observations from SAVOR-TIMI 53","volume":"65","author":"Zelniker","year":"2019","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.ijcard.2025.133554_bb0210","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","article-title":"Diabetes, heart failure, and renal dysfunction: the vicious circles","volume":"62","author":"Braunwald","year":"2019","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"4","key":"10.1016\/j.ijcard.2025.133554_bb0215","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.123.015298","article-title":"Cardioprotective effect of Empagliflozin and circulating ketone bodies during acute myocardial infarction","volume":"16","author":"Santos-Gallego","year":"2023","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2025.133554_bb0220","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ahj.2020.09.020","volume":"231","author":"Wiggers","year":"2021","journal-title":"Am. Heart J."},{"issue":"5","key":"10.1016\/j.ijcard.2025.133554_bb0225","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ejhf.1146","article-title":"Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes","volume":"20","author":"Cosmi","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"8","key":"10.1016\/j.ijcard.2025.133554_bb0230","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ejhf.1535","article-title":"Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction","volume":"21","author":"Shen","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.ijcard.2025.133554_bb0235","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ijcard.2025.133554_bb0240","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijcard.2025.133554_bb0245","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ijcard.2025.133554_bb0250","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.ijcard.2025.133554_bb0255","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijcard.2025.133554_bb0260","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"10456","key":"10.1016\/j.ijcard.2025.133554_bb0265","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet Lond. Engl."},{"issue":"5","key":"10.1016\/j.ijcard.2025.133554_bb0270","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2025.133554_bb0275","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jacc.2024.05.036","article-title":"The quest for understanding diabetic cardiomyopathy: can we preserve function and prevent failure?","volume":"84","author":"Lala","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2025.133554_bb0280","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jacc.2024.03.380","article-title":"Randomized trial of a selective aldose reductase inhibitor in patients with diabetic cardiomyopathy","volume":"84","author":"Januzzi","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2025.133554_bb0285","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"10.1016\/j.ijcard.2025.133554_bb0290","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.2337\/dc19-0587","article-title":"Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score","volume":"42","author":"Segar","year":"2019","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ijcard.2025.133554_bb0295","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2337\/dc21-1170","article-title":"A biomarker-based score for risk of hospitalization for heart failure in patients with diabetes","volume":"44","author":"Berg","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ijcard.2025.133554_bb0300","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2337\/dc20-2806","article-title":"Cluster analysis of cardiovascular phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine","volume":"45","author":"Sharma","year":"2022","journal-title":"Diabetes Care"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325005972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325005972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:48:37Z","timestamp":1776919717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527325005972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":60,"alternative-id":["S0167527325005972"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133554","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic cardiomyopathy revisited: The interplay between diabetes and heart failure","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"133554"}}